Endogenous inhibitors of nuclear factor-kappaB, an opportunity for cancer control

Area of Science:

• Molecular Biology
• Cell Biology
• Oncology

Background:

• Prolonged activation of nuclear factor-kappaB (NF-kappaB) is implicated in various human diseases, particularly cancer.
• NF-kappaB promotes the expression of genes involved in cell survival, inflammation, and metastasis.
• Cells possess intrinsic mechanisms to regulate NF-kappaB activity, involving inhibitory proteins and endogenous molecules.

Purpose of the Study:

• To review the known endogenous inhibitors of NF-kappaB.
• To explore the mechanisms by which NF-kappaB remains activated in cancer despite the presence of these inhibitors.

Main Methods:

• Literature review of studies on NF-kappaB regulation and cancer.
• Analysis of identified endogenous NF-kappaB inhibitors.
• Discussion of the paradox of sustained NF-kappaB activation in malignancies.

Main Results:

• Identified endogenous NF-kappaB inhibitors include A20, CYLD, cyPG15-deoxy-Delta(12,14)-prostaglandin J(2), Foxj1, Twist proteins, and beta-arrestins.
• These molecules negatively regulate NF-kappaB activation or activity.
• The existence of numerous antagonists raises questions about the mechanisms sustaining NF-kappaB activation in cancer.

Conclusions:

• The identified endogenous inhibitors offer potential therapeutic targets for cancer intervention.
• Further research is needed to elucidate how NF-kappaB signaling is sustained in cancer.
• Understanding these regulatory pathways could lead to novel anti-cancer strategies.